BioDlink Showcases Europe-China CMC Collaboration Amid Developmental Breakthrough
* Recognized as Biologics CDMO of the Year, BioDlink shares insights into the world's first approved EGFR-targeted ADC for recurrent/metastatic nasopharyngeal carcinoma * The company enables seamless Europe–China tech transfer and faster biologics development through an integrated, end-to-end...
BioDlink and Lepu Biopharma Celebrate Successful Launch of the World's First EGFR-Targeting ADC Drug, Marking a Major Milestone in Mutual Collaboration in Biologics CMC
* Celebrating a Shared Milestone: BioDlink and Lepu Biopharma celebrated the launch of MEIYOUHENG®, the world's first EGFR-Targeting ADC, and their partnership spanning over two years. * Demonstrating Robust Capabilities: Throughout the collaboration, all technology transfers and GMP manufact...
BioDlink Congratulates Lepu Biopharma on Securing Approval for the World's First Approved EGFR-Targeted ADC
* BioDlink helps Lepu Biopharma win China's marketing approval for EGFR-targeted ADC treating recurrent or metastatic nasopharyngeal carcinoma * This Becotatug Vedotin injection approval is BioDlink's first commercial ADC manufacturing initiative worldwide, validating its complex biologics co...
BioDlink Completes First International Shipment of Bevacizumab to Colombia
* Bevacizumab is a targeted therapy used to treat lung and colorectal cancers, both among the top three cancers ranked by death inColombia[1]. * This inaugural shipment—dispatched around two months after Colombia's marketing approval—demonstrates the company's efficiency, while validating its ...
SUCCESSFUL PASSING OF EU QP AUDIT ON TOT BIOPHARM'S COMMERCIAL PRODUCTION BASE FOR MONOCLONAL ANTIBODY DRUG SUBSTANCES AND ANTIBODY DRUG CONJUGATES
SUZHOU,China, Oct. 27, 2022 /PRNewswire/ -- TOT BIOPHARM International Company Limited (TOT BIOPHARM, Stock code: 1875.HK) has recently received a GMP compliance inspection report approved by aQualified Person ("QP") in the European Union ("EU") in respect of the manufacturing facilities and asso...
Connected Transactions Involving Subscription by Vivo Suzhou Fund and Centerlab for TOT BIOPHARM Shares
SUZHOU, China, June 2, 2022 /PRNewswire/ -- On June 1, 2022, TOT BIOPHARM International Company Limited (TOT BIOPHARM, Stock code: 1875.HK) announced that the company entered into a Share Subscription Agreement with VIVO Suzhou Fund and Centerlab. Pursuant to the agreement, Vivo Suzhou Fund and C...
TOT BIOPHARM Announces NMPA Granted Marketing Approval for Pusintin® (TAB008, Bevacizumab Injection) in China
SUZHOU, China, Dec. 2, 2021 /PRNewswire/ -- TOT BIOPHARM International Company Limited (TOT BIOPHARM, 1875.HK) announced its self-developed Pusintin® (TAB008, bevacizumab injection) has been officially granted approval by the National Medical Products Administration ("NMPA") for marketing in main...
TOT BIOPHARM Anounces 2021 Interim Results
Revenue Surges 78% to RMB23.13 million CDMO Business Achieves Leapfrog Breakthrough Two Products Approved for Launch Smooth Progress of Various Core Anti-tumor Drugs Clinical Trials To Allocate Resources to Boost Innovative ADC Drugs HONG KONG and SUZHOU, China, Aug. 13, 2021 /PRNewswire/ -- TOT B...
TOT BIOPHARM (1875.HK) Proceeded with IPO raising over HK$500 million
HONG KONG, Nov. 7, 2019 /PRNewswire/ -- A clinical-stage biopharmaceutical company with full industry value chain capabilities, TOT BIOPHARM International Company Limited ("TOT BIOPHARM" or the "Company", together with its subsidiaries, the "Group", stock code: 1875) was well received by the capi...
